The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
Abstract
Disease-modifying agents (DMAs), including interferon beta (IFNbeta) and glatiramer acetate (GA), are the mainstays of long-term treatment of multiple sclerosis (MS). Other potent anti-inflammatory agents like natalizumab and different types of chemotherapeutics are increasingly being used for treatment of MS, particularly in patients with breakthrough disease activity. Brain volume (BV) loss occurs early in the disease process, accelerates over time, and may be only partially affected by DMA therapy. Low-dose, low frequency IFNbeta administered once weekly and GA appear to partially reduce BV decline over the second and third years of treatment. High dose, high frequency IFNbeta demonstrated no clear effect on BV loss during this time period. Current evidence suggests that changes in BV after immunoablation may not be due entirely to the resolution of edema but may be related to potential chemotoxicity of high dose cyclophosphamide. Natalizumab reduces the development of BV decline in the second and third years of treatment. IV immunoglobulin showed a positive effect on decelerating BV reduction in relapsing and advanced stages of MS. These differences between DMAs may be explained by the extent of their therapeutic effects on inflammation and on the balance between inhibition or promotion of remyelination and neuronal repair in the CNS. We described the mechanisms of action by which DMAs induce accelerated, non-tissue-related BV loss (pseudoatrophy) in the short term but, in the long run, may still potentially lead to permanent BV decline. The effects of corticosteroid therapy on changes in BV in patients with MS help clarify the mechanisms through which potent anti-inflammatory treatments may prevent, stabilize, or induce BV loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Self-citationPremyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991
Why does remyelination fail in multiple sclerosis?
Franklin, R. J. M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn917 · Cited by 837
Remyelination is extensive in a subset of multiple sclerosis patients
Patrikios, P., Stadelmann, C., Kutzelnigg, A., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., Bruck, W., Lucchinetti, C., & Lassmann, H. (2006) · Brain · doi:10.1093/brain/awl217 · Cited by 807
Self-citationUse of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
Rudick, R. A., Fisher, E., Lee, J.-C., Simon, J., Jacobs, L., & the Multiple Sclerosis Collaborative Research Group (1999) · Neurology · doi:10.1212/wnl.53.8.1698 · Cited by 736
Aquaporins in Brain: Distribution, Physiology, and Pathophysiology
Badaut, J., Lasbennes, F., Magistretti, P. J., & Regli, L. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200204000-00001 · Cited by 541
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1496 · Cited by 475
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
Li, D. K. B., Zhao, G. J., Paty, D. W., & the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1505 · Cited by 458
The measurement and clinical relevance of brain atrophy in multiple sclerosis
Bermel, R. A., & Bakshi, R. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70349-0 · Cited by 456
Cited by
Targeting Huntingtin Expression in Patients with Huntington’s Disease
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900907 · Cited by 708
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression
Ascherio, A., Munger, K. L., White, R., Köchert, K., Simon, K. C., Polman, C. H., Freedman, M. S., Hartung, H.-P., Miller, D. H., Montalbán, X., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5993 · Cited by 516
Association between pathological and MRI findings in multiple sclerosis
Filippi, M., Rocca, M. A., Barkhof, F., Brück, W., Chen, J. T., Comi, G., DeLuca, G., De Stefano, N., Erickson, B. J., Evangelou, N., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70003-0 · Cited by 486
Self-citationon behalf of the MAGNIMS study group (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.157 · Cited by 473
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
Metadata
- Authors
- Zivadinov, R., Reder, A. T., Filippi, M., Minagar, A., Stüve, O., Lassmann, H., Racke, M. K., Dwyer, M. G., Frohman, E. M., & Khan, O.
- Venue
- Neurology
- Published
- 2008-07-08
- Volume
- 71
- Issue
- 2
- Pages
- 136-144
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1988037885
- Cited by
- 260
- References
- 51
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. https://app.cochat.ai/papers/10.1212/01.wnl.0000316810.01120.05
- The paper
- Zivadinov, R., Reder, A. T., Filippi, M., Minagar, A., Stüve, O., Lassmann, H., Racke, M. K., Dwyer, M. G., Frohman, E. M., & Khan, O. (2008). Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. https://doi.org/10.1212/01.wnl.0000316810.01120.05
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.